Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
The Biochemical Journal
|
July 17, 2010
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Christian C Lee, Yong Jia, Nanxin Li, et al.
European Journal of Medicinal Chemistry
|
February 13, 2026
Discovery of novel ENPP1 inhibitors with benzotriazole core for cancer immunotherapy
Junghwan Choi, Sunwoo Lee, Yong-Yea Park, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 1, 2008
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase
Wooyoung Hur, Anastasia Velentza, Sungjoon Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 23, 2006
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Anna V Galkin, Jonathan S Melnick, Sungjoon Kim, et al.
Journal of Medicinal Chemistry
|
November 14, 2023
Discovery of Orally Bioavailable Phthalazinone Analogues as an ENPP1 Inhibitor for STING-Mediated Cancer Immunotherapy
Yeonguk Cho, Miso Kang, Su Hyun Ji, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 12, 2016
Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors
Pierre-Yves Michellys, Bei Chen, Tao Jiang, et al.
Cancer Discovery
|
March 29, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer
Luc Friboulet, Nanxin Li, Ryohei Katayama, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 24, 2006
An efficient rapid system for profiling the cellular activities of molecular libraries
Jonathan S Melnick, Jeff Janes, Sungjoon Kim, et al.
Journal of Medicinal Chemistry
|
June 8, 2013
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials
Thomas H Marsilje, Wei Pei, Bei Chen, et al.
Nature
|
November 26, 2010
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M Johannessen, Jesse S Boehm, So Young Kim, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
The Biochemical Journal
|
July 17, 2010
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Christian C Lee, Yong Jia, Nanxin Li, et al.
European Journal of Medicinal Chemistry
|
February 13, 2026
Discovery of novel ENPP1 inhibitors with benzotriazole core for cancer immunotherapy
Junghwan Choi, Sunwoo Lee, Yong-Yea Park, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 1, 2008
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase
Wooyoung Hur, Anastasia Velentza, Sungjoon Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 23, 2006
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Anna V Galkin, Jonathan S Melnick, Sungjoon Kim, et al.
Journal of Medicinal Chemistry
|
November 14, 2023
Discovery of Orally Bioavailable Phthalazinone Analogues as an ENPP1 Inhibitor for STING-Mediated Cancer Immunotherapy
Yeonguk Cho, Miso Kang, Su Hyun Ji, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 12, 2016
Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors
Pierre-Yves Michellys, Bei Chen, Tao Jiang, et al.
Cancer Discovery
|
March 29, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer
Luc Friboulet, Nanxin Li, Ryohei Katayama, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 24, 2006
An efficient rapid system for profiling the cellular activities of molecular libraries
Jonathan S Melnick, Jeff Janes, Sungjoon Kim, et al.
Journal of Medicinal Chemistry
|
June 8, 2013
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials
Thomas H Marsilje, Wei Pei, Bei Chen, et al.
Nature
|
November 26, 2010
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M Johannessen, Jesse S Boehm, So Young Kim, et al.
Page
of 5